Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.58, $0.26 better than the analyst estimate of $3.32. Revenue for the quarter came in at $469.37 million versus the consensus estimate of $482.48 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2018 EPS of $12.75-$13.25, versus the consensus of $13.11. Jazz Pharmaceuticals sees FY2018 revenue of $1.86-1.9 million, versus the consensus of $1.92 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Berenberg Downgrades Siemens Healthineers (SHL:GR) (SEMHF) to Hold
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half